Abstract：
Convalescent plasma was proposed for passive immunization against COVID-19; but so far there are conflicting results and still open questions. However, besides antibodies, other plasma proteins may be good candidates for further research and application. Thromboinflammation frequently complicates severe COVID-19, and classical anticoagulants like heparins seem to have limited effect. The natural protease inhibitors antithrombin III (ATIII), α1-antitrypsin (α1-AT) and α2-macroglobulin (α2-M), which are found decreased in severe COVD-19, play a crucial role in prothrombotic and inflammatory pathways. While ATIII and α1-AT are licensed as commercially prepared therapeutic concentrates, there is no preparation of α2-M available. The diagnostic, prognostic, and even therapeutic potential of plasma protease inhibitors should be further explored.
摘要：
恢复期血浆被提议用于对COVID-19的被动免疫；但到目前为止，结果相互矛盾，仍然存在悬而未决的问题。然而,除了抗体,其他血浆蛋白可能是进一步研究和应用的良好候选者。血栓炎症经常使严重的COVID-19复杂化，经典的抗凝剂如肝素似乎效果有限。天然蛋白酶抑制剂抗凝血酶III（ATIII），α1-抗胰蛋白酶（α1-AT）和α2-巨球蛋白（α2-M），在重度COVD-19中发现降低，在血栓形成和炎症通路中起关键作用。虽然ATIII和α1-AT被许可作为商业制备的治疗浓缩物，没有可用的α2-M制剂。诊断，预后，甚至血浆蛋白酶抑制剂的治疗潜力应该进一步探索。
